Optimization of Therapy in Patients with Epilepsy and Psychiatric Comorbidities: Key Points
Francesco Pisani(University of Messina), Edoardo Spina(University of Messina), María Antonietta Barbieri(University of Messina), José de León(Hospital Santiago Apostol), Laura Rosa Pisani(Regenxbio (United States))
Cited by 26
Related Papers
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
|The Lancet|2019|640
Prevalence and Impact of Medical Comorbidity in Alzheimer's Disease
|The Journals of Gerontology Series A|2002|267
AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders
|Nature Communications|2019|252